ArticleAnnals of medicine and surgery (2012)2026
CFHR5 promotes colorectal cancer by upregulating COX4I2 to inhibit ferroptosis.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) remains one of the most common gastrointestinal malignancies worldwide, characterized by high incidence and mortality rates. Ferroptosis, an iron-dependent form of regulated cell death, has emerged as a critical mechanism in tumor biology. However, the regulatory role of CFHR5 (Complement Factor H-Related Protein 5) in ferroptosis and CRC progression remains unclear. Methods: We applied Mendelian randomization (MR) to evaluate the causal role of CFHR5 in CRC. Mediation MR was further employed to assess ferroptosis-related genes as potential mediators. Differential expression and correlation analyses were conducted using multiple CRC transcriptomic cohorts. Functional enrichment and Gene Set Variation Analysis (GSVA) were performed to investigate ferroptosis-related pathways. In addition, drug sensitivity prediction and molecular docking were carried out to identify potential therapeutic targets. Results: MR analysis demonstrated a significant positive association between CFHR5 expression and CRC risk (FinnGen: OR = 1.233, P = 0.004; UK Biobank: OR = 1.072, P < 0.001). Mediation MR identified COX4I2 as a key ferroptosis-related mediator, accounting for 16.4% and 21.8% of the total effect in Finnish and UK cohorts, respectively. Transcriptomic validation confirmed elevated CFHR5 and COX4I2 expression in CRC tissues, with a strong positive correlation between them. Enrichment analyses indicated that CFHR5-related genes were significantly involved in cholesterol metabolism, iron binding, and oxidative stress pathways. GSVA showed that CFHR5 expression was negatively correlated with ferroptosis-related pathways. Drug sensitivity analysis suggested that CFHR5 downregulation increased CRC cell sensitivity to ABT-737, while molecular docking revealed a strong binding affinity between CFHR5 and ABT-737 (binding energy: -9.4 kcal/mol). Conclusions: Our study demonstrates that CFHR5 promotes CRC progression by upregulating COX4I2 and inhibiting ferroptosis. These findings highlight CFHR5 as a promising biomarker and therapeutic target for CRC, warranting further validation in experimental and preclinical models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.